PhaSER Biomedical

About PhaSER Biomedical

PhaSER Biomedical is a Scotland-based biotechnology company established in October 2022 by Professor Roland Wolf. The company was founded to commercialize the 8HUM mouse model, a culmination of over 15 years and £17M in research and development. This extensive work was a collaborative effort involving the University of Dundee, CXR Biosciences, Taconic Farms, and was supported by Scottish Enterprise.

The company's core offering is the 8HUM transgenic mouse model, engineered to more accurately replicate human drug metabolism for pre-clinical research. This is achieved by replacing 33 murine cytochrome P450 enzymes and key transcription factors with their human equivalents, which are responsible for over 90% of P450-mediated drug metabolism in humans. This advanced model provides researchers with more precise predictions of human drug responses, pharmacokinetics, and potential drug-drug interactions, aiming to reduce the high attrition rates of drugs in clinical trials. PhaSER Biomedical supplies the 8HUM mice, immunodeficient variations for cancer research, and related subcellular fractions to its clients, which include pharmaceutical companies, universities, and charitable organizations.

PhaSER's business model centers on providing these specialized models and associated data to accelerate drug discovery and development programs. By offering a more reliable in vivo model, the company helps clients save time and resources that might otherwise be spent optimizing compounds for mouse-specific metabolic issues. In February 2024, the company received a significant $2.3 million grant from the Bill & Melinda Gates Foundation. This funding supports a three-year program to provide the 8HUM models to researchers within the Global Health Discovery Collaboratory Programme, focusing on diseases such as malaria, tuberculosis, and HIV.